Amylin Pharma Q2 Revenues Down
Amylin Pharma has posted a net loss, excluding a restructuring charge of $3.4m. Non-GAAP operating loss was $7.4m, a 67% improvement compared to $22.4m for the same period
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging